Recent developments for Profusa include multiple reverse stock splits executed in 2026, an option agreement to acquire G3 Vision Labs, leadership changes, and the launch of commercial products generating initial revenue.

• Profusa executed a 1-for-4 reverse stock split effective August 18, 2026, with the stock price rising 160% following the split [N2].
• The company announced and implemented the 1-for-4 reverse stock split in August 2026, with shares sliding in pre-market before the split [N3][N4].
• Profusa executed another reverse stock split in 2026, consolidating its share structure [N1].
• Profusa entered into an option agreement to acquire G3 Vision Labs, a health diagnostics and toxicology testing company, with the acquisition subject to multiple conditions including financing and approvals [N6].
• The company experienced a 19% stock price decline amid news of the diagnostics acquisition [N6].
• Profusa launched its Lumee™ Tissue Oxygen Healthcare Research offerings in January 2026, initiating first commercial revenue [N5].
• Leadership changes in 2026 included appointment of Jack Stover as Executive Chairman and CEO, and other board updates [S2].

Profusa's launch of Lumee™ and initiation of commercial revenue mark important milestones in product commercialization. The option agreement to acquire G3 Vision Labs could diversify and expand its diagnostics capabilities, potentially broadening its addressable market. Leadership changes may bring fresh strategic direction, and ongoing cybersecurity governance supports operational resilience. The company's efforts to consolidate its share structure through reverse stock splits may improve market perception and trading liquidity.

Profusa's financial position shows very low liquidity and significant net losses, raising concerns about operational sustainability. The acquisition of G3 Vision Labs presents integration risks, including potential disruption, unexpected costs, and dilution to existing shareholders. Multiple reverse stock splits may reflect challenges in maintaining share price levels. Leadership transitions could cause operational disruptions. The company's reliance on financing and approvals for acquisitions adds uncertainty to its strategic execution.

Profusa's moat is centered on its proprietary biosensing technology for tissue oxygen monitoring, with commercial offerings such as Lumee™ initiating revenue streams. The company's strategic partnerships, including with Mayo Clinic, and its focus on innovative health monitoring solutions contribute to its competitive positioning. However, the company faces challenges integrating new acquisitions outside its core biosensing focus, which may impact its ability to leverage synergies and expand its market presence effectively.

• Acquisition Integration Risk: The proposed acquisition of G3 Vision Labs is subject to multiple conditions and may not be completed. Integration challenges could disrupt operations, increase costs, and prevent realization of anticipated benefits.
• Liquidity and Financial Risk: As of June 30, 2026, Profusa has very low liquidity ratios with current assets of $841,000 against current liabilities of $28.2 million, indicating potential challenges in meeting short-term obligations.
• Dilution Risk: Issuance of Series A Non-Voting Convertible Preferred Stock and warrants related to acquisitions and financing may cause significant dilution to existing shareholders.
• Leadership Transition Risk: Recent significant changes in executive leadership may disrupt business operations and strategic execution.
• Cybersecurity Risk: Profusa faces cybersecurity threats that could compromise data and systems, leading to potential liabilities and operational disruptions, though governance and oversight mechanisms are in place.

• Profusa, Inc. is a Delaware corporation headquartered in Berkeley, California, United States.
• The company operates in the biosensing and health diagnostics sector, with a focus on tissue oxygen monitoring technologies.
• Profusa launched its Lumee™ Tissue Oxygen Healthcare Research offerings, initiating first commercial revenue as of January 2026.
• Profusa entered into an option agreement on July 31, 2026, to acquire G3 Vision Labs Inc. and its subsidiaries, which operate in the health diagnostics and toxicology testing market.
• The acquisition is subject to multiple conditions including financing of at least $30 million, refinancing of G3 indebtedness, stockholder and Nasdaq approvals, and execution of definitive acquisition documents.
• Profusa issued shares of common stock and Series A Non-Voting Convertible Preferred Stock as consideration related to the option agreement for G3 Vision Labs.
• The Series A Preferred Stock is convertible into common stock subject to stockholder approval, with potential for significant dilution to existing stockholders.
• Profusa has experienced significant changes in executive leadership in mid-2026, including appointment of Jack Stover as Executive Chairman and CEO and other board changes.
• The company has implemented multiple reverse stock splits in 2026, including a 1-for-25 split effective July 2026 and a 1-for-4 split effective August 2026.
• Profusa's liquidity as of June 30, 2026, shows cash and equivalents of $375,000 and current assets of $841,000 against current liabilities of $28,167,000, resulting in a current ratio of 0.03 and cash ratio of 0.01, indicating very low liquidity.
• Profusa reported a net loss of $8,755,000 for the quarter ended June 30, 2026, with basic and diluted EPS of -$151.80 per share.
• The company is not currently subject to any material legal proceedings.
• Profusa's Board of Directors and Audit Committee have established oversight mechanisms for cybersecurity risk management, with regular briefings and incident response plans.
• The company issued warrants in connection with debt financing, which may cause dilution and have anti-dilution provisions that could further dilute stockholders.
• Profusa's recent news includes multiple announcements and executions of reverse stock splits, acquisition option agreement news, and commercial product launches.
• The company has disclosed risks related to the acquisition of G3 Vision Labs, including integration challenges, potential disruption, and dilution risks.
• Profusa's management regularly informs the Board and Audit Committee on cybersecurity risks and incidents, with the CEO responsible for IT and cybersecurity oversight.